Posted: Wed Mar 25, 2009 8:24 pm Post subject: Xcellerex, Collaborators Receive Phase 2 Contract
Xcellerex, Inc., along with three collaborators, has been awarded an $11M Phase 2 contract by the Defense Threat Reduction Agency to develop technology for accelerated monoclonal antibody and vaccine manufacturing.
Xcellerex, which serves as the prime contractor, is collaborating with Dowpharmasm, a business unit of the Dow Chemical Company, Biopharm Services, and deltaDOT. The team combines Xcellerex’s microbial PDMax™ high speed process development and FlexFactory™ single-use manufacturing technologies with Dowpharma’s Pfēnex Expression TechnologyTM and deltaDOT’s Peregrine® label free CE-based analytical technology. The team is guided by BioPharm Services systems integration, data management/process economics, and simulated event modeling technology.
You cannot post new topics in this forum You cannot reply to topics in this forum You cannot edit your posts in this forum You cannot delete your posts in this forum You cannot vote in polls in this forum